2X Match My Gift
This National Cancer Survivors Month, your gift is matched to expand treatment options and bring more patients into survivorship through Project Cure CRC.

Colorectal cancer can spread to other parts of your body through your blood or lymphatic system. The liver is the most common site of metastasis in patients with colorectal cancer, due to the blood supply that exists between the large intestine and the liver.
While liver metastasis can be very challenging to stop, there are options to consider for treatment.
Surgery can play an important role in treating liver metastasis for many patients. However, not everyone is a candidate for liver surgery.
There are a number of therapies that use chemotherapy, HAI therapy, ablation, radiation, cryotherapy, heat, and other approaches to reduce or remove liver metastases.
Because liver directed therapies are localized and target just the tumor, much of the surrounding tissue is spared. Many of these therapies are minimally invasive and have a short recovery time.

For many cancer patients, the end of active treatment brings a new kind of dread. Scans every few months and anxious waits for results. A blood test is changing that experience for a growing number of patients.

When Helen was diagnosed with metastatic colorectal cancer, the biggest concern for her medical team was that her cancer had spread to her liver. One type of therapy, hepatic artery infusion, offered a path forward, but there was a catch. Nobody at her hospital had ever done it before. She'd have to be first.

hrough Project Cure CRC, the Alliance is fueling bold, early-stage research with the potential to transform colorectal cancer treatment. Dr. Lisa Mielke’s groundbreaking work explores how the gut’s immune system and nerve signaling influence cancer growth—opening the door to new therapeutic approaches, including repurposed existing drugs. This is what’s possible when promising ideas get the support they need to move forward.